Oregon PrEP at Home Study: Real-world Delivery of Long-acting Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP) Through a Tele-PrEP Program and a Home Infusion Program Partnership to Address Geographic PrEP Disparities in Oregon
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms OR-PrEP@Home
Most Recent Events
- 05 Dec 2023 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
- 05 Dec 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.